在接受免疫球蛋白和治疗性抗体的肿瘤血液病患者中，（1,3）-β-D-葡聚糖的假阳性率很高。
High False-Positive Rate of (1,3)-β-D-Glucan in Onco-Hematological Patients Receiving Immunoglobulins and Therapeutic Antibodies.
机构信息
Infectious Diseases Service, University Hospital and University of Lausanne, Lausanne, Switzerland.
Hematology Service, University Hospital and University of Lausanne, Lausanne, Switzerland.
出版信息
Clin Infect Dis. 2022 Aug 25;75(2):330-333. doi: 10.1093/cid/ciab1028.
PMID:34996098
Abstract
Immunoglobulins and/or therapeutic antibody preparations are associated with a high rate of false-positive (1,3)-β-D-glucan (BDG) tests in onco-hematological patients routinely screened for fungal infections. The benefit of BDG monitoring shall be balanced against the risk of false-positive tests leading to unnecessary investigations and costs in this population.
摘要
免疫球蛋白和/或治疗性抗体制剂与肿瘤血液病患者中真菌感染常规筛查时（1,3）-β-D-葡聚糖（BDG）试验的高假阳性率相关。在该人群中，BDG 监测的益处应与假阳性试验导致不必要的检查和费用的风险相平衡。
Zotero 插件